V. Lokesh Battula: Our findings on resistance to Fluorothymidine 3 inhibitors in Acute Myeloid Leukemia are now published in the Leukemia Journal

V. Lokesh Battula, Associate Professor at MD Anderson Cancer Center, shared on LinkedIn:

“Happy to report that our findings on resistance to FLT3 inhibitors in AML are now published in the Leukemia Journal. In this report, we have reported ACVR1 as a novel resistance factor for FLT3 inhibitors in AML and introduced a novel FLT3-ACVR1 dual inhibitor (TP-0184) as a single agent to target both FLT3 and its resistance factor in AML!”

Read the article here.
Source: V. Lokesh Battula/LinkedIn